Clinical bottom line
AI-enhanced imaging techniques offer promising advances for the early detection of Alzheimer’s disease (AD), potentially improving diagnostic accuracy and enabling earlier intervention. Current evidence supports the integration of machine learning algorithms with structural and functional imaging modalities to identify subtle brain changes preceding clinical symptoms. However, these technologies remain largely investigational, with challenges in validation, standardization, and clinical implementation. Careful interpretation alongside clinical and neuropsychological assessments remains essential (Düzel et al., 2025; Elble et al., 2020).
What the evidence shows
Early diagnosis of AD is critical for timely management and planning. Traditional imaging approaches, including MRI and PET, provide structural and molecular insights but often detect changes only after significant neurodegeneration.
Düzel et al. (2025) review recent advances in AI applications to imaging for AD, highlighting machine learning models that analyze volumetric MRI, functional connectivity, and PET amyloid/tau imaging to detect preclinical and prodromal stages. These AI tools can identify complex patterns of atrophy and metabolic dysfunction with higher sensitivity than conventional visual assessment.
Elble et al. (2020) emphasize that combining AI-enhanced imaging with clinical and neuropsychological data improves diagnostic confidence, particularly in mild cognitive impairment (MCI) populations at risk for progression to AD.
López-de-Ipiña et al. (2017) discuss advanced biomedical signal processing methods, including deep learning, that extract subtle imaging biomarkers, enabling earlier detection than standard metrics.
Cappa et al. (2025) provide an overview of current diagnostic strategies, underscoring the potential of AI to standardize interpretation and reduce inter-rater variability in imaging assessments.
Caveats and uncertainty
Despite promising results, most AI-enhanced imaging studies are limited by small sample sizes, retrospective designs, and lack of external validation. Variability in imaging protocols and populations complicates generalizability.
The clinical utility of AI tools in routine practice is not yet established, with limited data on impact on patient outcomes or cost-effectiveness. Ethical and regulatory considerations around AI deployment in neuroimaging remain evolving.
Interpretation of AI outputs requires expertise, and false positives or negatives may occur, necessitating integration with comprehensive clinical evaluation.
How this may change practice
AI-enhanced imaging may become an important adjunct in the diagnostic workup of patients with cognitive complaints, facilitating earlier and more accurate identification of AD pathology.
Radiologists and neurologists should stay informed about emerging AI tools and consider multidisciplinary collaboration to interpret findings within clinical context.
Future workflows may incorporate AI algorithms for automated quantification and risk stratification, potentially improving patient selection for disease-modifying therapies as they become available.
Ongoing research and standardization efforts are needed before widespread clinical adoption.